




Constitutional genetic testing in BC: updates to ordering molecular genetic and cytogenetic tests at the Division of Genome Diagnostics.

Dr. Lindsay Brown, PhD, FCCMG Clinical Molecular Geneticist and Cytogeneticist
Dr. Elizabeth Digby, MD, FRCPC, FCCMG Medical Geneticist
Dr. Emma Strong, PhD, FCCMG Clinical Molecular Geneticist

Disclosures



- The authors declare no conflicts of interest.



Learning objectives



- Recognize when specific genetic tests may or may not be indicated for your patients;
- Identify and utilize resources that support ordering constitutional genetic tests;
- Support multidisciplinary partnership between Pediatrics and Medical Genetics by identifying clinical scenarios that may require additional testing prior to referral to Medical Genetics.

Outline



- 1) Brief introduction to Division of Genome Diagnostics and the Provincial Medical Genetics Program;
- 2) Review common clinical scenarios, genetic tests to consider and requirements or considerations prior to referral to medical genetics;
- 3) Review how to order genetic testing and improvements made to this process;
- 4) Highlight resources available to support ordering of genetic tests.

Introductions



Division of Genome Diagnostics, Provincial Laboratory

- Constitutional molecular genetic and pediatric cytogenetic testing across lifetime
- Provide consultative support to Physicians;
- Test development and implementation

Provincial Medical Genetics Program

- Evaluation and diagnosis of congenital anomalies and genetic disease across lifetime
- Genetic counselling regarding chance of occurrence or recurrence of genetic disease
- Inpatient, outpatient, outreach consultations
- Education about medical genetics for health care professionals and others

Division of Genome Diagnostics



Molecular Genetic tests:

- Fragile X syndrome;
- Prader-Willi syndrome;
- Spinal Muscular Atrophy (SMA);
- Type 1 Myotonic Dystrophy

Cytogenetic tests:

- Chromosomal microarray (CMA);
- Karyotype;
- Targeted fluorescent *in-situ* hybridization (FISH)



Case example 1

Case example 1



- 3 year old male with global developmental delay.

Genetic tests to consider:

- Chromosomal microarray (CMA)
- Fragile X syndrome

Indications for CMA



Currently the clinical utility of CMA has been recognized by many professional societies and recommended as a **first-tier genetic test** for patients with **unexplained GDD/ID, ASD, and/or multiple congenital anomalies**

Indications for Fragile X syndrome testing



- Males or females with global developmental delay (GDD) or intellectual disability (ID) of unknown etiology, with or without Autism Spectrum Disorder;
- *For individuals with developmental delay, ID or GDD must be suspected (multiple domains impacted)

Utility of Fragile X syndrome testing



- In individuals with ID, the diagnostic rate has been reported as **0-2.5%** in recent literature*
- The diagnostic yield increases to **9.5-17%** with increased specificity of testing (PMIDs: 19786505, 29624914, 8859272):
 - males with intellectual disability AND
 - characteristic physical and behavioural features OR
 - family history suggestive of Fragile X syndrome

* PMIDs: 32152462, 28541279, 28914265, 28933791, 28933790. See also Fragile X FAQ at www.genebc.ca

Common clinical features of Fragile X syndrome



Clinical feature	Frequency in Fragile X syndrome	Frequency in ID (without FXS)	Clinical Score
Skin soft and velvety on the palms with redundancy on the dorsum of the hands	88%	52%	2
Flat feet	70%	37%	2
Large and prominent ears	84%	22%	2
Plantar crease	86%	23%	1
Large testicles (post-puberty)	71%	10%	1
Family history of ID	81%	24%	1
Autistic-like behaviour	76%	25%	1

- Adapted from Table 2 in Lubala *et al* 2018
PMID: 29624914

- Meta-analysis of clinical features of Fragile X syndrome

- ID was a prerequisite for inclusion in this study

- A score ≥ 5 had a significant yield of Fragile X diagnoses

Case example 1



- 3 year old male with developmental delay spanning multiple domains.
- Meets classification of global developmental delay.

Prior to referral to Medical Genetics

- Arrange (and provide and results of) available in province genetic testing
- Provide copies of any developmental assessments/psychoeducational testing
- Consultation note documenting any congenital anomalies, distinctive features, and/or pertinent family history
 - Relevant imaging studies and consultations, if applicable

Case example 2

Case example 2

- 7 year old male with mild autism spectrum disorder.
- No history of GDD, learning difficulties in school (reading) but no intellectual disability.

Genetic tests to consider:

- Chromosomal microarray

Clinical Utility of CMA



- Diagnostic yields associated with phenotypes (PMID: 31781653)
 - Isolated GDD/ID – 18%
 - GDD/ID with epilepsy – 17%
 - GDD/ID with multiple congenital anomalies – 35%
 - Isolated ASD – 4%
- Isolated ASD (~4-5%) had lower diagnostic yield than those patients with ASD and syndromic features (~25%) (PMID: 27975050, 29564645, 33394245)
- Higher diagnostic yield has been reported for moderate to severe ID (20-30%) than for mild ID (12-19%) (PMID: 26511719, 24297458)

Severe and complex phenotypes have a higher likelihood of identifying a genetic etiology

Utility of Fragile X syndrome testing



- Evidence-based publications do not support testing for Fragile X syndrome in individuals with isolated ASD
 - The diagnostic rate has been reported as **0%** in recent literature (PMID: 28541279)

Case example 2



- 7 year old male with mild autism spectrum disorder.
- No history of GDD, learning difficulties in school (reading) but no intellectual disability.

Prior to referral to Medical Genetics

- Referral largely not indicated
- Evaluate for additional features suspicious for underlying syndromic diagnosis
 - ID, congenital anomalies, distinctive features, very severe autism diagnosed at a very young age (particularly affecting girls), multiple severely affected siblings, concomitant ID cannot be ruled out and is highly suspected
- Consider providing recurrence chance counselling based on empiric data*

* PMIDs: 28973142

Case example 3



Case example 3



- 8 year old male with isolated ADHD.
- No history of GDD, intellectual disability or congenital anomalies.

Genetic testing not indicated.

Isolated behavioural disorders



- No studies evaluating diagnostic yield of CMA for isolated speech or motor delay or learning disability
- Lack of demonstrated utility for isolated behavioural disorders.
 - One study reported detection rate of ~8-9% in patients with ADHD (PMID: 31602316)
 - Lack of clinical information to determine if ADHD isolated or associated with GDD/ID
 - Many CNVs were inherited - clinical significance unclear and do not distinguish pathogenic vs VUS
 - Studies have shown that patients with ADHD had similar frequency of rare CNVs to that of controls (PMID: 19546859, 21832240).

Case example 3



- 8 year old male with isolated ADHD.
- No history of GDD, intellectual disability, or congenital anomalies.

Referral to Medical Genetics not indicated



Case example 4

Case example 4




- 7 year old female with ID, CMA shows copy number variant of uncertain significance (VUS)

Genetic testing to arrange

- Parental follow-up variant assessment, as directed by test report
- May need samples from both parent and proband

Parental follow up variant assessment



FISH

- Requires NaHep sample
- Sample from parents and proband



CMA

- Do not require proband sample
- EDTA sample from parents needed



Karyotype

- Requires NaHep sample
- Sample from parents and proband

CNV Classification



Recommended variant classification categories

(ACMG technical standards; PMID: 31690835)

- Pathogenic
- Likely pathogenic
- Uncertain significance (VUS)
- Likely benign*
- Benign*

*not included on clinical report

Interpretation and reporting of CNVs



Variants of uncertain significance (VUS)

- CNV described in a small number of cases in general population
- Contains genes that are unknown if dosage sensitive
- CNV described in multiple contradictory publicns and/or databases

Reporting of VUS can be challenging – goal of clinical interpretation and reporting is maximize return of useful diagnostic findings. Also to eliminate uncertainty and burden of further testing for families (avoid misinterpretation).

Parental follow up variant assessment



914 CNVs

~40% Path (367)

~60% VUS (547)

128 parental follow up testing

198 with parental follow up testing


~55% De novo (70)

~45% Inherited (58)

~14% de novo (28)

~86% inherited (170)

Interpretation and reporting of CNVs



Variants of uncertain significance (VUS)

- >80% are inherited (likely from healthy parent) and follow up testing does not change variant classification (i.e. does not change classification to likely pathogenic)
 - ^{NTI3} Questions the utility of this testing
- Finding of a VUS (or even a 'negative' CMA) does not exclude a genetic diagnosis
 - Many VUS are unlikely to be disease causing
 - Additional testing may be warranted to identify genetic etiology for patients clinical features
 - Referral to PMGP

NT[3 edit?

Nelson, Tanya [CWBC], 5/10/2022

Case example 4



- 7 year old female with ID, CMA shows copy number variant of uncertain significance

Prior to referral to Medical Genetics

- Please arrange parentals and wait for them to be reported **prior** to initiating referral as this is necessary for triage
- Provide copies of any developmental assessments/psychoeducational testing
- Consultation note documenting any congenital anomalies, dysmorphic features, and/or pertinent family history
 - Relevant imaging studies and consultations, if applicable
- *****Exception***** you do not need to arrange parentals for pathogenic, likely pathogenic, or neurosusceptibility copy number variants
 - These parents may benefit from consenting discussion prior to appointment and these referral are prioritized



Case examples 5 & 6

Case example 5



- Newborn infant with hypotonia

Genetic testing to consider prior to referral to Medical Genetics

- CMA
- Prader-Willi Methylation Studies
- Spinal Muscular Atrophy Exon 7-8 Deletion Testing
- Myotonic Dystrophy Type 1 Repeat Expansion Testing
- Pompe enzyme assay

Case example 6



- 16M with tall stature and hypermobility ?Marfan syndrome

Prior to referral to Medical Genetics

- Calculate systemic score:
<https://marfan.org/dx/>
- Arrange and provide echocardiogram
- Arrange and provide ophthalmology assessment
- Provide pertinent family history

Scoring of systemic features.

Feature	YES	NO
Wrist AND thumb sign	3	0
Wrist OR thumb sign	1	0
Pectus carinatum deformity	2	0
pectus excavatum or chest asymmetry	1	0
Hindfoot deformity	2	0
Plain flat foot	1	0
Pneumothorax	2	0
Dural ectasia	2	0
Protrusio acetabulae	2	0
Reduced US/LS and increased armspan/height	1	0
Scoliosis or thoracolumbar kyphosis	1	0
Reduced elbow extension	1	0
3/5 facial features	1	0
Skin striae	1	0
Myopia	1	0
Mitral valve prolapse	1	0

No genetic testing indicated prior to referral

How do I order genetic testing?



- All test requests require the appropriate test requisition form and clinical indications for testing must be provided

Quality improvement updates:

- 1 requisition: constitutional genetic test requisition
- Many clinical indications provided on 2nd page for ease of completion
- Only 2 mL EDTA necessary (unless NaHep also required)

Where can I find more information?



- www.genebc.ca

- Test requisition form
- Tests currently available
- Test information, including indications
- FAQs for common scenarios
- Information on how to apply for out-of-province testing
- Contact information for further enquiries

Division of Genome Diagnostics
at BC Children's Hospital & BC Women's Hospital

Select Conditions/Tests...
Select Gene...

HOME TEST MENU FORMS POLICIES & PROTOCOLS FOR PROVIDERS OUTSIDE BC FREQUENTLY ASKED QUESTIONS

Select Language

Powered by Translate

Division DAP accredited laboratories provide genetic analysis for a select test menu of inherited disorders affecting children and adults.
CCMG-certified Molecular Geneticists and Cytogeneticists provide test interpretation and consultation.
Currently, samples are only accepted from residents of Canada.

Welcome to the Division of Genome Diagnostics website.

Contact
BC Children's & BC Women's Hospitals
4500 Oak Street, Vancouver B.C. V6H 0N1
Molecular Genetics
Tel: 604-875-2852
Fax: 604-875-2707
Email: [Click here](#) to send an email.

The Division of Genome Diagnostics is responsible for providing academic pediatric, adult, and maternal-fetal medicine care for the province of BC.
Genome Diagnostics is a Division of the Tier 1 Department of Pathology and Laboratory Medicine at BC Children's and BC Women's Hospitals.
The hospital labs are accredited in Laboratory Medicine by the Diagnostic Accreditation Program (DAP) of BC.

Where can I find more information?



www.genebc.ca

If you would like a word version of our requisition to build into your EMR, please contact us at:

moleculargenetics@cw.bc.ca

Division of Genome Diagnostics
at BC Children's Hospital & BC Women's Hospital

Select Conditions/Tests...
Select Gene...

Select Language
Powered by Translate

HOME TEST MENU FORMS POLICIES & PROTOCOLS FOR PROVIDERS OUTSIDE BC FREQUENTLY ASKED QUESTIONS

Division *DAP* accredited laboratories provide genetic analysis for a select [test menu](#) of inherited disorders affecting children and adults.
CCMG-certified Molecular Geneticists and Cytogeneticists provide test interpretation and consultation.
Currently, samples are only accepted from residents of Canada.

Welcome to the Division of Genome Diagnostics website.

The Division of Genome Diagnostics is responsible for providing academic pediatric, adult, and maternal-fetal medicine care for the province of BC.

Genome Diagnostics is a Division of the Tier 1 Department of Pathology and Laboratory Medicine at BC Children's and BC Women's Hospitals.

The hospital labs are accredited in Laboratory Medicine by the Diagnostic Accreditation Program (DAP) of BC.

Contact

BC Children's & BC Women's Hospitals
4500 Oak Street, Vancouver B.C. V6H 3N1

Molecular Genetics
Tel: 604-675-2852
Fax: 604-675-2707
Email: [Click here](#) to send an email.